Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1928 1
1929 1
1950 1
1951 1
1952 1
1953 4
1954 1
1955 1
1956 1
1957 1
1958 2
1961 2
1962 2
1964 3
1969 1
1970 1
1975 1
1976 1
1977 1
1981 1
1985 1
1986 3
1988 2
1989 3
1990 1
1991 1
1992 2
1993 10
1994 7
1995 8
1996 10
1997 4
1998 10
1999 13
2000 18
2001 14
2002 12
2003 16
2004 8
2005 6
2006 5
2007 8
2008 5
2009 5
2010 3
2011 9
2012 10
2013 13
2014 13
2015 19
2016 25
2017 23
2018 28
2019 25
2020 20
2021 16
2022 12
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 11641591

397 results

Results by year

Filters applied: . Clear all
Page 1
Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS).
Lechat P, Lardoux H, Mallet A, Sanchez P, Derumeaux G, Lecompte T, Maillard L, Mas JL, Mentre F, Pousset F, Lacomblez L, Pisica G, Solbes-Latourette S, Raynaud P, Chaumet-Riffaud P; FFAACS (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané) Investigators. Lechat P, et al. Cerebrovasc Dis. 2001;12(3):245-52. doi: 10.1159/000047711. Cerebrovasc Dis. 2001. PMID: 11641591 Clinical Trial.
[Study of combined anticoagulant (fluindione)-aspirin therapy in patients with atrial fibrillation at high risk for thromboembolic complications. A randomized trial (FFAACS)].
Lechat P, Lardoux H, Mallet A, Sanchez P, Derumeaux G, Lecompte T, Maillard L, Mas JL, Mentré F, Pousset F, Lacomblez L, Pisica G, Solbes-Latourette S, Raynaud P, Chaumet-Riffaud P; Investigateurs de FFAACS. Lechat P, et al. Therapie. 2000 Nov-Dec;55(6):681-9. Therapie. 2000. PMID: 11234463 Clinical Trial. French.
Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL; SPORTIF Investigators. Flaker GC, et al. Am Heart J. 2006 Nov;152(5):967-73. doi: 10.1016/j.ahj.2006.06.024. Am Heart J. 2006. PMID: 17070169
Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE, Rosenfeld LE, Mitrani G, Nemeth M; AFFIRM Investigators. DiMarco JP, et al. Am Heart J. 2005 Apr;149(4):650-6. doi: 10.1016/j.ahj.2004.11.015. Am Heart J. 2005. PMID: 15990748 Clinical Trial.
397 results